Switzerland's Lonza has negotiated exclusive rights to an
expression system, used in the manufacture of therapeutic proteins,
that could be used to shorten the development time for its
customers' biologic products.
France's Nautilus Biotech says that it has achieved a key technical
milestone in a collaboration with Aventis Pasteur, designed to
improve the productivity of the latter's vaccine manufacturing